Utah Medical Products (NASDAQ:UTMD – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.
Profitability
This table compares Utah Medical Products and TriSalus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Utah Medical Products | 33.40% | 13.06% | 12.30% |
| TriSalus Life Sciences | N/A | N/A | -221.65% |
Earnings and Valuation
This table compares Utah Medical Products and TriSalus Life Sciences’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Utah Medical Products | $49.04 million | 4.83 | $16.64 million | $4.50 | 14.93 |
| TriSalus Life Sciences | $18.51 million | 8.29 | -$59.04 million | N/A | N/A |
Institutional & Insider Ownership
69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 6.6% of Utah Medical Products shares are held by company insiders. Comparatively, 76.2% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Utah Medical Products has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Utah Medical Products and TriSalus Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Utah Medical Products | 0 | 0 | 0 | 0 | N/A |
| TriSalus Life Sciences | 0 | 0 | 3 | 0 | 3.00 |
TriSalus Life Sciences has a consensus target price of $13.33, suggesting a potential upside of 135.99%. Given TriSalus Life Sciences’ higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than Utah Medical Products.
Summary
Utah Medical Products beats TriSalus Life Sciences on 6 of the 11 factors compared between the two stocks.
About Utah Medical Products
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.
